Palisade Bio Inc (PALI)

Overview News Price History Discussions Forecast Stock Split

Palisade Bio Inc stock is currently priced at $4.71, with a 24-hour trading volume of 144.74K. It has seen a -7.10% decreased in the last 24 hours and a +1,173% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $5.44 pivot point. If it approaches the $4.54 support level, significant changes may occur.

Palisade Bio Inc Stock (PALI) Financials Data

Palisade Bio Inc (PALI) Net Income 2024

PALI net income (TTM) was -$12.30 million for the quarter ending December 31, 2023, a +13.74% increase year-over-year.

Palisade Bio Inc (PALI) Cash Flow 2024

PALI recorded a free cash flow (TTM) of -$11.13 million for the quarter ending December 31, 2023, a +16.67% increase year-over-year.

Palisade Bio Inc (PALI) Earnings per Share 2024

PALI earnings per share (TTM) was -$1.81 for the quarter ending December 31, 2023, a +92.52% growth year-over-year.

Palisade Bio Inc Stock (PALI) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Neal James R	Director	Feb 09 '24	Option Exercise	0.00	10,920	0	10,920
Trenschel Robert J.	Director	Feb 08 '24	Option Exercise	0.00	10,920	0	10,920
Csimma Cristina	Director	Feb 08 '24	Option Exercise	0.00	12,800	0	12,862
Diaz Stephanie	Director	Feb 08 '24	Option Exercise	0.00	12,800	0	12,800
Finley John David	CEO, CFO, Director	Feb 06 '24	Option Exercise	0.00	6,642	0	91,291
Jones Mitchell Lawrence	Chief Medical Officer	Feb 06 '24	Option Exercise	0.00	6,891	0	9,815
Finley John David	CEO, CFO, Director	Feb 06 '24	Buy	0.47	10,000	4,692	84,649
Williams Donald Allen	Director	Jan 31 '24	Buy	0.60	10,000	6,050	30,000
Finley John David	CEO, CFO, Director	Jan 31 '24	Buy	0.56	10,000	5,590	74,649
Finley John David	CEO, CFO, Director	Jan 03 '24	Option Exercise	0.00	1,309	0	64,649

Palisade Bio Inc Stock (PALI) Latest News

S&P 500 Edges Lower; PacBio Shares Plunge

Benzinga

Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™

GlobeNewswire Inc.

Palisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress, such as results from reduced blood flow to the intestine, infections, and surgery. The company was founded in 2005 and is based in Carlsbad, California.